Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis
Authors:
- 8 February 2024
- journal article
- review article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (6) , 1334-1341
Abstract
Background: Persistent pulmonary hypertension of the newborn is a life-threatening condition that affects about 1–2 per 1,000 live births worldwide. Bosentan is an oral dual endothelin receptor antagonist that may have a beneficial effect on persistent pulmonary hypertension of the newborn by reducing pulmonary vascular resistance and improving oxygenation. However, its role in persistent pulmonary hypertension of the newborn remains unclear.Objectives: To systematically evaluate the efficacy and safety of bosentan as an adjuvant therapy for persistent pulmonary hypertension of the newborn in newborns.Methods: We searched six English and two Chinese databases from their inception to 1 January 2023 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We included randomised controlled trials and retrospective studies that compared bosentan with placebo or other drugs for persistent pulmonary hypertension of the newborn in newborns. We performed a meta-analysis using random-effects models and assessed the risk of bias and heterogeneity in the included studies.Results: We included 10 studies with a total of 550 participants. Bosentan significantly reduced the treatment failure rate (relative risk = 0.25, P < 0.001), pulmonary artery pressure (mean difference = −11.79, P < 0.001), and length of hospital stay (mean difference = −1.04, P = 0.003), and increased the partial pressure of oxygen (mean difference = 10.02, P < 0.001) and blood oxygen saturation (SpO2) (mean difference = 8.24, P < 0.001) compared with a placebo or other drugs. The occurrence of adverse reactions was not significantly different between bosentan and a placebo or other drugs.Conclusions: Bosentan is effective in the treatment of persistent pulmonary hypertension of the newborn but adverse reactions such as abnormal liver function should be observed when using it.Keywords
This publication has 28 references indexed in Scilit:
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial HypertensionCirculation, 2012
- Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan useEuropean Journal of Pediatrics, 2011
- Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants with Chronic Lung DiseaseThe Journal of Pediatrics, 2009
- Ambrisentan for the Treatment of Pulmonary Arterial HypertensionCirculation, 2008
- Left Ventricular Diastolic Dysfunction in Bronchopulmonary DysplasiaThe Journal of Pediatrics, 2008
- Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentanEuropean Journal of Pediatrics, 2007
- Results of European post-marketing surveillance of bosentan in pulmonary hypertensionEuropean Respiratory Journal, 2007
- Neonatal Persistent Pulmonary Hypertension Treated with Milrinone: Four Case ReportsNeonatology, 2006
- Hemodynamics and Survival of Patients With Portopulmonary HypertensionLiver Transplantation, 2005